Who Paid My Doc
Acticor 7 VR-T DX
Device Cardiology/Vascular Diseases
PDI 04035479156701
General payments
$2,593,791
Research payments
$2,314,028
Through program year 2025, $2,593,791 in general payments and $2,314,028 in research payments were reported against Acticor 7 VR-T DX (Cardiology/Vascular Diseases).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
9 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $147,899 | 2,286 |
| 2025 | Research | $176,819 | 100 |
| 2024 | General | $349,493 | 2,087 |
| 2024 | Research | $438,913 | 1,712 |
| 2023 | General | $397,443 | 1,803 |
| 2023 | Research | $746,143 | 3,788 |
| 2022 | General | $1,698,955 | 4,526 |
| 2022 | Research | $943,455 | 5,645 |
| 2021 | Research | $8,698 | 4 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 33 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 48 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
10,702 general · 11,249 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.